NO20060553L - 2-4-(fenylamino)-piperidin-1-YL!-N-fenyl-acetamin derivater og beslektede sammensetninger som neuropeptid Y5 (NPY5) ligander for behandling av fedme - Google Patents

2-4-(fenylamino)-piperidin-1-YL!-N-fenyl-acetamin derivater og beslektede sammensetninger som neuropeptid Y5 (NPY5) ligander for behandling av fedme

Info

Publication number: NO20060553L
Authority: NO; Norway
Prior art keywords: disorders; neuropeptide; treatment; npy5; obesity
Prior art date: 2003-07-30

Application number

NO20060553A

Other languages

English (en)

Norwegian (no)

Inventor

Josep Mas Prio

Maria Angeles Fisas Escasany

Torrens Jover Antoni

Original Assignee

Esteve Labor Dr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-30

Filing date

2006-02-02

Publication date

2006-02-02

2006-02-02 Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr

2006-02-02 Publication of NO20060553L publication Critical patent/NO20060553L/no

Links

238000011282 treatment Methods 0.000 title abstract 3
108090000189 Neuropeptides Proteins 0.000 title abstract 2
102000003797 Neuropeptides Human genes 0.000 title abstract 2
208000008589 Obesity Diseases 0.000 title abstract 2
235000020824 obesity Nutrition 0.000 title abstract 2
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 title 1
239000003446 ligand Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
230000029087 digestion Effects 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
238000011321 prophylaxis Methods 0.000 abstract 2
-1 1,2-disubstituted piperidine compounds Chemical class 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
101100460788 Arabidopsis thaliana NPY5 gene Proteins 0.000 abstract 1
208000032841 Bulimia Diseases 0.000 abstract 1
206010006550 Bulimia nervosa Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
101150111774 NPY5R gene Proteins 0.000 abstract 1
108050002826 Neuropeptide Y Receptor Proteins 0.000 abstract 1
102000012301 Neuropeptide Y receptor Human genes 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
208000022531 anorexia Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
230000037406 food intake Effects 0.000 abstract 1
235000012631 food intake Nutrition 0.000 abstract 1
230000001631 hypertensive effect Effects 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Manufacturing & Machinery (AREA)
Pain & Pain Management (AREA)
Ceramic Engineering (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Inorganic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Structural Engineering (AREA)
Materials Engineering (AREA)
Rheumatology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20060553A 2003-07-30 2006-02-02 2-4-(fenylamino)-piperidin-1-YL!-N-fenyl-acetamin derivater og beslektede sammensetninger som neuropeptid Y5 (NPY5) ligander for behandling av fedme NO20060553L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES200301813A ES2222833B1 (es)	2003-07-30	2003-07-30	Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
PCT/EP2004/008508 WO2005013988A1 (en)	2003-07-30	2004-07-29	2-`4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatement of obesity

Publications (1)

Publication Number	Publication Date
NO20060553L true NO20060553L (no)	2006-02-02

Family

ID=34130546

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20060553A NO20060553L (no)	2003-07-30	2006-02-02	2-4-(fenylamino)-piperidin-1-YL!-N-fenyl-acetamin derivater og beslektede sammensetninger som neuropeptid Y5 (NPY5) ligander for behandling av fedme
NO20060605A NO20060605L (no)	2003-07-30	2006-02-07	2-4-(hydroxymethyl-fenylamino)-piperidin-1-YL!-N-(9H-carbazol-3-YL)-acetamin derivater og beslektede forbindelser som neuropeptid Y5 (NPY5) ligander for behandling av fedme

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20060605A NO20060605L (no)	2003-07-30	2006-02-07	2-4-(hydroxymethyl-fenylamino)-piperidin-1-YL!-N-(9H-carbazol-3-YL)-acetamin derivater og beslektede forbindelser som neuropeptid Y5 (NPY5) ligander for behandling av fedme

Country Status (19)

Country	Link
US (4)	US7888510B2 (de)
EP (2)	EP1651220B1 (de)
JP (2)	JP2007500169A (de)
CN (2)	CN1832745A (de)
AR (1)	AR045154A1 (de)
AT (2)	ATE348615T1 (de)
AU (2)	AU2004262482A1 (de)
BR (2)	BRPI0413091A (de)
CA (2)	CA2534096A1 (de)
DE (2)	DE602004003831T2 (de)
ES (3)	ES2222833B1 (de)
MX (2)	MXPA06001140A (de)
MY (1)	MY136965A (de)
NO (2)	NO20060553L (de)
PE (1)	PE20050332A1 (de)
PT (2)	PT1651220E (de)
RU (2)	RU2006105711A (de)
TW (1)	TW200510379A (de)
WO (2)	WO2005013990A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9560804B1 (en)	2010-12-15	2017-02-07	Marion Calmer	Stalk roll with flutes defining a recess
ES2222833B1 (es) *	2003-07-30	2006-03-01	Laboratorios Del Dr. Esteve, S.A.	Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
EP1918281A1 (de) *	2006-11-02	2008-05-07	Laboratorios del Dr. Esteve S.A.	Phenylamino-substituierte piperidine Verbindungen, ihre Herstellung und Verwendung als Arzneimittel
EP2129219A4 (de)	2007-02-16	2012-08-29	Synta Pharmaceuticals Corp	Substituierte annelierte verbindungen für entzündungs- und immunbedingte verwendung
CN102272120B (zh) *	2008-11-07	2013-12-25	H.隆德贝克有限公司	生物活性酰胺
AU2021324684A1 (en) *	2020-08-11	2023-04-20	Board Of Trustees Of Michigan State University	Proteasome enhancers and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7692996A (en)	1995-12-01	1997-06-27	Ciba-Geigy Ag	Receptor antagonists
AU1328197A (en)	1995-12-01	1997-06-19	Synaptic Pharmaceutical Corporation	Aryl sulfonamide and sulfamide derivatives and uses thereof
US6043246A (en)	1996-12-03	2000-03-28	Banyu Pharmaceutical Co., Ltd.	Urea derivatives
US6048900A (en) *	1998-02-13	2000-04-11	Bayer Corporation	Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
WO1998035957A1 (en) *	1997-02-14	1998-08-20	Bayer Corporation	Amide derivatives as selective neuropeptide y receptor antagonists
AU6309698A (en)	1997-03-12	1998-09-29	Banyu Pharmaceutical Co., Ltd.	Drugs containing aminopyridine derivatives as the active ingredient
US7534857B2 (en) *	1997-12-19	2009-05-19	Centegen, Inc.	Methods and compositions for the treatment and prevention of staphylococcal infections
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
NZ510988A (en)	1998-10-07	2005-01-28	Ortho Mcneil Pharm Inc	N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor
WO2001007409A1 (en) *	1999-07-23	2001-02-01	Astrazeneca Uk Limited	Carbazole derivatives and their use as neuropeptide y5 receptor ligands
US6399631B1 (en) *	1999-07-23	2002-06-04	Pfizer Inc.	Carbazole neuropeptide Y5 antagonists
HUP0202143A3 (en) *	1999-07-28	2003-12-29	Ortho Mcneil Pharm Inc	Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
WO2001013917A1 (en)	1999-08-26	2001-03-01	Bristol-Myers Squibb Company	Npy antagonists: spiroisoquinolinone derivatives
KR100890676B1 (ko) *	2001-07-24	2009-03-26	리히데 게데온 베기에스제티 기아르 알티	신규한 카르복시산 아미드 화합물
US7067549B2 (en) *	2001-12-31	2006-06-27	Actelion Pharmaceuticals Ag	Pyrrolidone carboxamides
ES2193875B2 (es) *	2002-04-09	2005-03-01	Laboratorios Del Dr. Esteve, S.A.	Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2228267B1 (es) *	2003-07-30	2006-07-01	Laboratorios Del Dr. Esteve, S.A.	Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222833B1 (es) *	2003-07-30	2006-03-01	Laboratorios Del Dr. Esteve, S.A.	Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.

2003
- 2003-07-30 ES ES200301813A patent/ES2222833B1/es not_active Expired - Fee Related
2004
- 2004-07-29 ES ES04741322T patent/ES2279400T3/es not_active Expired - Lifetime
- 2004-07-29 AR ARP040102696A patent/AR045154A1/es unknown
- 2004-07-29 BR BRPI0413091-0A patent/BRPI0413091A/pt not_active Application Discontinuation
- 2004-07-29 US US10/565,979 patent/US7888510B2/en not_active Expired - Fee Related
- 2004-07-29 CN CNA2004800222637A patent/CN1832745A/zh active Pending
- 2004-07-29 DE DE602004003831T patent/DE602004003831T2/de not_active Expired - Lifetime
- 2004-07-29 MY MYPI20043075A patent/MY136965A/en unknown
- 2004-07-29 AU AU2004262482A patent/AU2004262482A1/en not_active Abandoned
- 2004-07-29 RU RU2006105711/04A patent/RU2006105711A/ru unknown
- 2004-07-29 EP EP04741322A patent/EP1651220B1/de not_active Expired - Lifetime
- 2004-07-29 AU AU2004262491A patent/AU2004262491A1/en not_active Abandoned
- 2004-07-29 RU RU2006105792/04A patent/RU2006105792A/ru unknown
- 2004-07-29 PT PT04741322T patent/PT1651220E/pt unknown
- 2004-07-29 CA CA002534096A patent/CA2534096A1/en not_active Abandoned
- 2004-07-29 BR BRPI0412860-5A patent/BRPI0412860A/pt not_active IP Right Cessation
- 2004-07-29 WO PCT/EP2004/008517 patent/WO2005013990A1/en not_active Ceased
- 2004-07-29 PT PT04763608T patent/PT1648458E/pt unknown
- 2004-07-29 EP EP04763608A patent/EP1648458B1/de not_active Expired - Lifetime
- 2004-07-29 MX MXPA06001140A patent/MXPA06001140A/es not_active Application Discontinuation
- 2004-07-29 US US10/566,399 patent/US20070105853A1/en not_active Abandoned
- 2004-07-29 AT AT04741322T patent/ATE348615T1/de not_active IP Right Cessation
- 2004-07-29 JP JP2006521533A patent/JP2007500169A/ja active Pending
- 2004-07-29 CA CA002534101A patent/CA2534101A1/en not_active Abandoned
- 2004-07-29 DE DE602004003829T patent/DE602004003829T2/de not_active Expired - Lifetime
- 2004-07-29 MX MXPA06001226A patent/MXPA06001226A/es not_active Application Discontinuation
- 2004-07-29 ES ES04763608T patent/ES2279419T3/es not_active Expired - Lifetime
- 2004-07-29 CN CNA2004800219418A patent/CN1829516A/zh active Pending
- 2004-07-29 JP JP2006521526A patent/JP2007500162A/ja active Pending
- 2004-07-29 WO PCT/EP2004/008508 patent/WO2005013988A1/en not_active Ceased
- 2004-07-29 TW TW093122665A patent/TW200510379A/zh unknown
- 2004-07-29 AT AT04763608T patent/ATE348614T1/de not_active IP Right Cessation
- 2004-08-02 PE PE2004000734A patent/PE20050332A1/es not_active Application Discontinuation
2006
- 2006-02-02 NO NO20060553A patent/NO20060553L/no not_active Application Discontinuation
- 2006-02-07 NO NO20060605A patent/NO20060605L/no not_active Application Discontinuation
2010
- 2010-07-12 US US12/834,211 patent/US20100280072A1/en not_active Abandoned
2011
- 2011-01-06 US US12/985,646 patent/US20110172270A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE602004003831T2 (de)	2007-10-25
CA2534096A1 (en)	2005-02-17
US7888510B2 (en)	2011-02-15
US20100280072A1 (en)	2010-11-04
ES2279419T3 (es)	2007-08-16
BRPI0413091A (pt)	2006-10-03
MXPA06001226A (es)	2006-05-15
AR045154A1 (es)	2005-10-19
EP1648458B1 (de)	2006-12-20
WO2005013988A8 (en)	2006-11-09
EP1651220A1 (de)	2006-05-03
CN1832745A (zh)	2006-09-13
MY136965A (en)	2008-12-31
WO2005013988A1 (en)	2005-02-17
ES2222833A1 (es)	2005-02-01
MXPA06001140A (es)	2006-04-24
CN1829516A (zh)	2006-09-06
CA2534101A1 (en)	2005-02-17
US20070105853A1 (en)	2007-05-10
EP1651220B1 (de)	2006-12-20
JP2007500162A (ja)	2007-01-11
ES2222833B1 (es)	2006-03-01
DE602004003829T2 (de)	2007-09-20
PT1651220E (pt)	2007-03-30
TW200510379A (en)	2005-03-16
ATE348615T1 (de)	2007-01-15
US20110172270A1 (en)	2011-07-14
DE602004003829D1 (de)	2007-02-01
DE602004003831D1 (de)	2007-02-01
RU2006105711A (ru)	2007-09-20
BRPI0412860A (pt)	2006-10-03
JP2007500169A (ja)	2007-01-11
AU2004262482A1 (en)	2005-02-17
AU2004262491A1 (en)	2005-02-17
WO2005013990A1 (en)	2005-02-17
PT1648458E (pt)	2007-03-30
US20080119516A1 (en)	2008-05-22
PE20050332A1 (es)	2005-06-12
RU2006105792A (ru)	2007-09-20
ATE348614T1 (de)	2007-01-15
ES2279400T3 (es)	2007-08-16
EP1648458A1 (de)	2006-04-26
NO20060605L (no)	2006-02-07

Legal Events

Date	Code	Title	Description
2009-02-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
JP5578785B2 (ja)	2014-08-27	イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
BRPI0408910A (pt)	2006-03-21	composto, composição farmacêutica e métodos para a profilaxia ou o tratamento de doenças ou condições e para a produção de uma composição farmacêutica
JP5014994B2 (ja)	2012-08-29	イオンチャネルのモジュレーターとして有用なキナゾリン
NO20063780L (no)	2006-10-27	Fremgangsmate for fremstilling av 2-aminitiazol-5-aromatisk karboksamid som kinase inhibitorer.
DE602007007614D1 (de)	2010-08-19	Substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
CN1564685A (zh)	2005-01-12	吡咯烷酮衍生物
NO20091054L (no)	2009-03-09	Benzimidazolderivater anvendelige for behandling av vallinoidreceptor TRPV1 relaterte forstyrrelser
NO20050745L (no)	2005-05-23	Nye amidforbindelser med MCH-antagonistisk effekt, og medikamenter inneholdende slike forbindelser
RU2004129780A (ru)	2005-04-10	Производные аминоиндазолов, способ получения и промежуточные продукты этого способа в качестве лекарственных средств и содержащие их фармацевтические композиции
NZ595432A (en)	2013-12-20	4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
WO2006029153A3 (en)	2006-05-26	Monocyclic anilide spirolactam cgrp receptor antagonists
EP1796678A4 (de)	2009-09-02	Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
WO2003065989A3 (en)	2004-02-19	(oxime)carbamoyl fatty acid amide hydrolase inhibitors
TW200700068A (en)	2007-01-01	Phthalazine, aza-and diaza-phthalazine compounds and methods of use
NO20084403L (no)	2008-11-14	Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I
DE602005008558D1 (de)	2008-09-11	Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
RU2010120808A (ru)	2011-11-27	Производное амина, обладающее активностью антагониста npy y5 рецептора, и его применение
EA200801738A1 (ru)	2008-12-30	Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
ATE406353T1 (de)	2008-09-15	Piperidin-derivaten und deren verwendung bei der behandlung von durch chemokinen oder h1 vermittelten krankheiten
RU2010119530A (ru)	2011-11-27	Замещенные n-фенилпирролидинилметилпирролидинамиды и их терапевтическое применение в качестве модуляторов рецептора н3 гистамина
CN1455766A (zh)	2003-11-12	治疗免疫疾病的新的1,2－二苯基乙烯衍生物
CY1111429T1 (el)	2015-08-05	1,3-διυποκατεστημενα αμιδια 4-μεθυλο-1η-πυρρολο-2-καρβονικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
TW200626152A (en)	2006-08-01	Pyridine derivatives and pharmaceutical compositions and uses thereof
BG108941A (en)	2005-12-30	Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
NZ598505A (en)	2013-01-25	1,2-dihydro-2-oxoquinoline compounds as 5-ht4 receptor ligands